EAM
IKT icon

Exome Asset Management’s Inhibikase Therapeutics IKT Stock Holding History

Exome Asset Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-600,000
Closed -$1.23M – 65
2025
Q4 		$1.23M Buy
+600,000
New +$955K 0.59% 48

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Exome Asset Management's IKT Position: Q1 2026 in Review

Exome Asset Management sold out of Inhibikase Therapeutics (IKT) in Q1 2026, closing a stake of 600,000 shares — an estimated $1.23M sold.

Exome Asset Management first reported a position in IKT in Q4 2025 and held it in 1 quarter. The position peaked at $1.23M in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Exome Asset Management reported no remaining Inhibikase Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Exome Asset Management sold 600,000 Inhibikase Therapeutics shares in Q1 2026, an estimated $1.23M.
  • Exome Asset Management first reported a position in Inhibikase Therapeutics in Q4 2025 and held it in 1 quarter.
  • Exome Asset Management's Inhibikase Therapeutics position peaked at $1.23M in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.